For most infected individuals, HIV leads inexorably to CD4+ T cell depletion and profound immunodeficiency. For a fortunate few HIV infection results in extremely limited viral replication and peripheral CD4+ T cell counts are maintained. These patients, termed 'Elite Controllers', have been subject to intensive study since understanding how they control the virus should inform the vaccine effort. A large GWAS of ECs identified several non-synonymous amino acid changes in the peptide binding pocket of HLA-B that are associated with the EC phenotype. Those mutations, however, were only responsible for ~20% of the observed effect, and it has been suggested that much rarer, 'private'mutations that would not be uncovered by even a larger GWAS are responsible for the majority of the EC phenotype. I wish to identify those rare genetic mutations that may be contributing to the exquisite control o HIV in ECs. To do so, I propose whole exome sequencing (WES) of genomic DNA from ECs. Our group has completed WES of ~24 ECs and already has several promising gene leads;we now wish to expand exome sequencing to dozens of other ECs throughout the U.S. and world. Patient populations include Ethiopians (in collaboration with investigators in Addis Ababa and Makele), Spaniards (from a large cohort of ECs that are substance users), Chinese, and U.S. Veterans (many of whom have substance use as their HIV acquisition risk factor). Candidate genes identified from WES will be subjected to in vitro functional studies. Importantly, we have identified a subset of ECs who have cell-intrinsic resistance to HIV. Those ECs will allow us to explore the genetics of elite control, with a focus on family studies, in order to determine inheritance patterns and causative genes. In the end I hope to have identified genetic factors responsible for host control of HIV.

Public Health Relevance

Some individuals infected with HIV do not suffer any ill effects or need to take antiviral medications. We would like to find out why that is, and to do so we plan to sequence their DNA and compare it against individuals who do develop illness. Any genes that might be involved in controlling HIV will be thoroughly tested in different models, and it is hoped that by the identification of these genes we will achieve a much better understanding of how man might be able to control HIV in the absence of medications.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-SXC-E (03))
Program Officer
Lin, Yu
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Internal Medicine/Medicine
Schools of Medicine
New Haven
United States
Zip Code
Yue, Yan; Coskun, Ayse K; Jawanda, Navneet et al. (2018) Differential interaction between human and murine Crm1 and lentiviral Rev proteins. Virology 513:1-10
Gonzalo-Gil, Elena; Ikediobi, Uchenna; Sutton, Richard E (2017) Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers. Yale J Biol Med 90:245-259
Hu, Yani; O'Boyle, Kaitlin; Auer, Jim et al. (2017) Multiple UBXN family members inhibit retrovirus and lentivirus production and canonical NF?? signaling by stabilizing I?B?. PLoS Pathog 13:e1006187
Zhang, Xinyu; Justice, Amy C; Hu, Ying et al. (2016) Epigenome-wide differential DNA methylation between HIV-infected and uninfected individuals. Epigenetics :1-11
Liu, Shan; Jackson, Andrew; Beloor, Jagadish et al. (2015) Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized Mice. Hum Gene Ther 26:622-34